US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide ...

New research led by the University of Washington found that wildfire smoke is especially hazardous to people's memory health. An analysis of the health care records of 1.2 million Southern California ...

The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab ...

GlaxoSmithKline (GSK) has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its regulatory ...

From ground-breaking developments in energy systems to key advances in defence, low carbon mobility and healthcare technology ...

In this Q&A, He discussed Boehringer's investments in AI as well as areas where the technology could deliver greater value for pharma.

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...

GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...

GSK PLC said on Monday that the US Food & Drug Administration accepted a biologics license application for its Blenrep combinations for the treatment of relapsed and refractory multiple myeloma, both ...

GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...